key: cord-0844581-cwfy74i2
authors: Bal, Antonin; Destras, Grégory; Simon, Bruno; Giannoli, Jean-Marc; Morfin, Florence; Lina, Bruno; Josset, Laurence
title: Investigation of vaccine breakthrough infections by vaccination scheme during the delta variant wave in France
date: 2022-03-11
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.034
sha: 291cd0c428779241ae428d00a31f440806e824c9
doc_id: 844581
cord_uid: cwfy74i2

nan

1 vaccination scheme during the Delta variant wave in France 2 Antonin Bal 1,2 *, Grégory Destras 1,2 *, Bruno Simon 1,2 *, Jean-Marc Giannoli 3 , Florence 3

Morfin 1,2 , Bruno Lina 1,2 , Laurence Josset 1,2 , IVAC study group. 4 *equal contributions 5 1 Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre 6

National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, 7

France. 8 2 CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, 9

Inserm,U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-10 69007, Lyon, France. with interquartile range (IQR) and compared using non-parametric Kruskal-Wallis tests. 35

Proportions were compared using the chi-squared or Fisher's exact test as appropriate. A p-36 value of <0.05 was regarded as statistically significant. Statistical analyses were conducted 37 using R software, version 4.0.5 (R Foundation for Statistical Computing). CoV-2 genomic regions according to the vaccination scheme. 55

The median age of Delta-VBI cases significantly differed depending on the vaccination scheme 56 with a median below 50 years old except for Ad26.COV2.S and ChadOx1 groups (p<0.001). 57

Delta-VBI were mainly symptomatic (mild symptoms) for all vaccination schemes (> 69% of 58 symptomatic infections for all groups); limited RT-PCR Ct-values differences at diagnosis 59 were noticed in symptomatic than asymptomatic Delta-VBI for BNT162b2 group (17.7 (15.07,  60 20.51) vs 19.00 (16.00, 23.00), p=0.004). Interestingly, more than 75% of Delta-VBI occurred 61 in patients who were infected within three months after full vaccination, regardless of the 62 vaccination scheme. Besides, up to 50% of Delta-VBI were classified as early-VBI (infected 63 less than one month after full vaccination scheme) for BNT162b2, mRNA-1273, ChadOx1, and 64

Ad26.COV2.S (supplementary Table) . People aged 14-49 years were overrepresented in early 65 VBI compared to non-early VBI for BNT162b2 and mRNA-1273 (73.92% vs 37.87% for 66

BNT162b2 and 77.78% vs 46.67 % for mRNA-1273, p<0.05, Figure 1) . 67

Our data showed that mild VBI detected in community laboratories during the spread of Delta 68 variant mainly occurred within three months after full vaccination for all vaccination scheme. The main limitations of this study are related to the French vaccine policies explaining the 78 limited sample sizes for ChadOx1/BNT162b2 and Ad26.COV2.S groups and differences in 79 vaccination date between age groups and vaccine types. Importantly, BNT162b2 was the most 80 frequent vaccine reported herein which is consistent with the distribution of vaccine types 81 administered in France during the study period. Furthermore, full vaccination scheme with 82 ChadOx1 or Ad26.COV2.S was recommended in patients aged > 55 years old. This explains 83 the differences found herein between age and comorbidies according to the vaccine scheme. 84

Yet our data emphasize a high prevalence of early Delta-VBI in young patients that might be 85 

Ethics approval was obtained from the national review board for biomedical research (Comité 105

de Protection des Personnes Centre-Ouest I, France; ID-RCB 2021-A01877-34), and the study 106 was registered on ClinicalTrials.gov (NCT05060939). 107

No external funding was received for this study. 

Characterisation of 122 vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral 123 load dynamics in the community

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines | NEJM n.d. 126

Immunogenicity and 128 efficacy of heterologous ChadOx1/BNT162b2 vaccination

Transmission of 131 B.1.617.2 Delta Variant between vaccinated healthcare workers

Taux d'incidence de l'épidémie de COVID-19 (SI-DEP) -data.gouv.fr n.d